Futures fell after Trump said the U.S. will raise tariffs on more than $500 billion worth of Chinese imports, increasing trade tensions.Marketsread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
Hours after President Trump said Sunday he had "second thoughts" about escalating the trade war with China, the White House sought to explain his remark because it was...Politicsread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Despite Kudlow's expectations, China said on Saturday that it strongly opposes Trump's decision to levy additional tariffs on $550 billion worth of Chinese goods, and warned...Politicsread more
President Donald Trump said Sunday he was not happy after North Korea launched short-range ballistic missiles over the weekend.Politicsread more
Bryn Mawr Trust CIO Jeffrey Mills lists where to put money to work as Wall Street copes with trade war and recession jitters.Futures Nowread more
The announcement for Target also comes on the heels of a strong quarterly earnings report, where it showed it drove more people to stores and got them to spend more money...Retailread more
The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Idorsia founder and CEO Jean-Paul Clozel said his biotech group has the resources to assess trial data and decide what to do with assets, as spending on projects led to a 386 million Swiss franc ($385 million) loss in 2018.
The Swiss company still has total liquidity of 1.22 billion francs, down from 1.35 billion francs on Sept. 30.
Clozel, who spun Idorsia out of Actelion after that drugmaker's $30 billion sale in 2017 to Johnson & Johnson, last year initiated four late-stage trials of medicines, including against insomnia, brain bleeding, resistant hypertension and rare Fabry Disease.
Clozel, who said Idorsia "cut the umbilical cord" from Actelion over the course of 2018, sees operating expenses of around 570 million francs in the current year, up from 432 million last year, as trials on these and other molecules advance.
"The level of financing required for a diversified drug pipeline can pose certain challenges for a young company," Clozel said in a statement. "The 505 million francs raised in July 2018 should give us the necessary leeway to assess the clinical data for our late-stage pipeline and then make the appropriate strategic decisions regarding commercialisation."